Palmisciano Paolo, Watanabe Gina, Conching Andie, Ogasawara Christian, Ferini Gianluca, Bin-Alamer Othman, Haider Ali S, Sabini Maria Gabriella, Cuttone Giacomo, Cosentino Sebastiano, Ippolito Massimo, Umana Giuseppe E
Department of Neurosurgery, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI 96822, USA.
Cancers (Basel). 2022 Jun 14;14(12):2925. doi: 10.3390/cancers14122925.
The development of [Ga]Ga-DOTA-SSTR PET tracers has garnered interest in neuro-oncology, to increase accuracy in diagnostic, radiation planning, and neurotheranostics protocols. We systematically reviewed the literature on the current uses of [Ga]Ga-DOTA-SSTR PET in brain tumors.
PubMed, Scopus, Web of Science, and Cochrane were searched in accordance with the PRISMA guidelines to include published studies and ongoing trials utilizing [Ga]Ga-DOTA-SSTR PET in patients with brain tumors.
We included 63 published studies comprising 1030 patients with 1277 lesions, and 4 ongoing trials. [Ga]Ga-DOTA-SSTR PET was mostly used for diagnostic purposes (62.5%), followed by treatment planning (32.7%), and neurotheranostics (4.8%). Most lesions were meningiomas (93.6%), followed by pituitary adenomas (2.8%), and the DOTATOC tracer (53.2%) was used more frequently than DOTATATE (39.1%) and DOTANOC (5.7%), except for diagnostic purposes (DOTATATE 51.1%). [Ga]Ga-DOTA-SSTR PET studies were mostly required to confirm the diagnosis of meningiomas (owing to their high SSTR2 expression and tracer uptake) or evaluate their extent of bone invasion, and improve volume contouring for better radiotherapy planning. Some studies reported the uncommon occurrence of SSTR2-positive brain pathology challenging the diagnostic accuracy of [Ga]Ga-DOTA-SSTR PET for meningiomas. Pre-treatment assessment of tracer uptake rates has been used to confirm patient eligibility (high somatostatin receptor-2 expression) for peptide receptor radionuclide therapy (PRRT) (i.e., neurotheranostics) for recurrent meningiomas and pituitary carcinomas.
[Ga]Ga-DOTA-SSTR PET studies may revolutionize the routine neuro-oncology practice, especially in meningiomas, by improving diagnostic accuracy, delineation of radiotherapy targets, and patient eligibility for radionuclide therapies.
[镓]镓 - DOTA - SSTR正电子发射断层显像（PET）示踪剂的研发引起了神经肿瘤学界的关注，有望提高诊断、放射治疗计划及神经诊疗方案的准确性。我们系统回顾了有关[镓]镓 - DOTA - SSTR PET在脑肿瘤中当前应用的文献。
按照PRISMA指南检索了PubMed、Scopus、Web of Science和Cochrane数据库，纳入已发表的研究以及正在进行的关于[镓]镓 - DOTA - SSTR PET在脑肿瘤患者中的试验。
我们纳入了63项已发表的研究，涉及1030例患者及1277个病灶，还有4项正在进行的试验。[镓]镓 - DOTA - SSTR PET主要用于诊断目的（62.5%），其次是治疗计划（32.7%）和神经诊疗（4.8%）。大多数病灶为脑膜瘤（93.6%），其次是垂体腺瘤（2.8%），除诊断目的外（镓标记奥曲肽51.1%），多靶点肽受体显像剂（53.2%）的使用频率高于镓标记生长抑素（39.1%）和镓标记氮杂环辛四肽（5.7%）。[镓]镓 - DOTA - SSTR PET研究大多用于确诊脑膜瘤（因其高生长抑素受体2表达及示踪剂摄取）或评估其骨侵袭范围，并改善体积轮廓以优化放射治疗计划。一些研究报告了生长抑素受体2阳性脑病变的罕见情况，这对[镓]镓 - DOTA - SSTR PET诊断脑膜瘤的准确性提出了挑战。术前评估示踪剂摄取率已用于确认复发性脑膜瘤和垂体癌患者接受肽受体放射性核素治疗（即神经诊疗）的资格（高生长抑素受体 - 2表达）。
[镓]镓 - DOTA - SSTR PET研究可能会彻底改变常规神经肿瘤学实践，尤其是在脑膜瘤方面，通过提高诊断准确性、明确放射治疗靶点以及确定患者接受放射性核素治疗的资格。
